Abstract:Despite recent technological advancements in cell tumor DNA (ctDNA) mutation detection, challenges persist in identifying low-frequency mutations due to inadequate sensitivity and coverage of current procedures. Herein, we introduce a super-sensitivity and specificity technique for detecting ctDNA mutations, named HiCASE. The method utilizes PCR-based CRISPR, coupled with the restriction enzyme. In this work, HiCASE focuses on testing a series of EGFR mutations to provide enhanced detection technology for non–small cell lung cancer (NSCLC), enabling a detection sensitivity of 0.01% with 40 ng cell free DNA standard. When applied to a panel of 140 plasma samples from 120 NSCLC patients, HiCASE exhibits 88.1% clinical sensitivity and 100% specificity with 40 μL of plasma, higher than ddPCR and Super-ARMS assay. In addition, HiCASE can also clearly distinguish T790M/C797S mutations in different positions at a 1% variant allele frequency, offering valuable guidance for drug utilization. Indeed, the established HiCASE assay shows potential for clinical applications.

What problem does this paper attempt to address?

### What problems does this paper attempt to solve? This paper aims to solve the challenges faced in the detection of circulating tumor DNA (ctDNA) mutations, especially the problem of detecting low - frequency EGFR mutations in plasma samples of non - small - cell lung cancer (NSCLC) patients. Although progress has been made in ctDNA mutation detection technology in recent years, the existing methods still have deficiencies in sensitivity and coverage, and it is difficult to identify low - frequency mutations. Specifically, this study introduced an ultrasensitive and highly specific detection technique named HiCASE (High - sensitivity PCR - Cas13a with Specific restriction Enzyme detection). HiCASE combines PCR amplification, restriction endonuclease (RE) digestion and the CRISPR/Cas13a system to improve the sensitivity and specificity of detection. The following are the main problems solved by this paper: 1. **Improve detection sensitivity**: Existing PCR - based methods such as ARMS and digital PCR (ddPCR) have limited sensitivity (0.2% - 1%) when detecting low - frequency mutations, while HiCASE can increase the detection sensitivity to 0.01%, significantly improving the ability to detect low - frequency mutations. 2. **Distinguish mutations at different positions**: HiCASE can clearly distinguish the different positions (cis or trans) of T790M and C797S mutations, which is of great significance for guiding the application of targeted drugs. 3. **Clinical application potential**: By validating 140 plasma samples of NSCLC patients, HiCASE has demonstrated its potential in clinical applications, showing 88.1% clinical sensitivity and 100% specificity, which is superior to ddPCR and Super - ARMS methods. 4. **Reduce the required sample volume**: HiCASE can perform effective detection with only a small amount of plasma (such as 40 μL), reducing the sample requirements and improving the feasibility and economy of detection. In conclusion, this paper proposes a new detection method, HiCASE, aiming to overcome the limitations of existing technologies in low - frequency mutation detection and provide a more effective tool for the accurate diagnosis and treatment of non - small - cell lung cancer patients.

CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma